Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours: A Phase 2 Study
In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate)
will be personalized, i.e. administered activity of LuTate will be tailored for each patient
to maximize absorbed radiation dose to tumour, while limiting that to healthy organs.
The purpose of this study is to:
- Assess the objective (radiological), symptomatic and biochemical response rates
following an induction course of personalized PRRT;
- Assess the overall, the disease-specific, and the progression-free survival following
- Correlate therapeutic response and survival with tumour absorbed radiation dose;
- Evaluate the acute, subacute and chronic adverse events following P-PRRT;
- Correlate toxicity (i.e. occurence and severity of adverse events) with absorbed
radiation doses to organs at risk;
- Optimize the quantitative SPECT imaging-based dosimetry methods in a subset of 20
patients (sub-study funded by the Canadian Institutes of Health Research).
This study also has a compassionate purpose, which is to provide access to PRRT to patients.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society